APA (7th ed.) Citation

Morikawa, T., Naiki, T., Sugiyama, Y., Naiki-Ito, A., Nagai, T., Etani, T., . . . Yasui, T. (2024). C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study. Cancers, 16(9), 1725. https://doi.org/10.3390/cancers16091725

Chicago Style (17th ed.) Citation

Morikawa, Toshiharu, et al. "C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study." Cancers 16, no. 9 (2024): 1725. https://doi.org/10.3390/cancers16091725.

MLA (9th ed.) Citation

Morikawa, Toshiharu, et al. "C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study." Cancers, vol. 16, no. 9, 2024, p. 1725, https://doi.org/10.3390/cancers16091725.